1 |
ADRA2A
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| [14] 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
2 |
ADRA2B
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| [14] 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
3 |
ADRA2C
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| [14] 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
4 |
PTGS2
| [22] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00567
D00567
|
Celecoxib
| [10] 2 2, 3, 34, 46, 70, 89, 107, 161, 171, 271 |
5 |
SLC6A2
| [1] Synaptic vesicle cycle Synaptic vesicle cycle | D07591
D07591
|
Bupropion
| [1] 171 171 |
6 |
SLC6A3
| [7] Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D07591
D07591
|
Bupropion
| [5] 8 8, 18, 21, 96, 171 |